Instrument Inactif

Communiqués IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Actions

ICCM

IL0011224156

Equipement et technologie médicale avancés

Communiqués

24/08	IceCure Medical : Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands	PU
17/08	IceCure Medical : Initial Statement of Beneficial Ownership (Form 3)	PU
06/08	IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026	AQ
30/07	IceCure, SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense	AQ
28/07	IceCure Medical Kicks Off its Post-Marketing ChoICE Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site	AQ
06/07	IceCure Medical : Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer	PU
23/06	IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer	PR
18/05	IceCure Medical : Initial Statement of Beneficial Ownership (Form 3)	PU
13/05	IceCure Medical : Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement	PU
06/05	IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026	PR
05/05	IceCure Medical : Showcases ProSense® Cryoablation at American Society of Breast Surgeons 2026 Annual Meeting as Commercial Momentum Accelerates in the U.S. Market	PU
26/03	IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study, 89.4% and 83.9% Recurrence-Free Rates	AQ
26/03	IceCure Announces Pricing of $4.0 Million Registered Direct Offering and Concurrent Private Placement	PR
25/03	IceCure Reports Positive 5-Year Top-Line Results from ICESECRET Kidney Cancer Cryoablation Study: 89.4% and 83.9% Recurrence-Free Rates	PR
17/03	IceCure Reports 2025 Full Year Financial & Operational Results	PR
15/03	IceCure Medical : Company Presentation	PU
11/03	U.S. FDA Approves IceCure's Post-Marketing "ChoICE" Study for ProSense® Cryoablation in the Local Treatment of Low-Risk Breast Cancer	PR
10/03	IceCure Medical to Report 2025 Full Year Financial and Operating Results on March 17, 2026	PR
09/03	American Society of Breast Surgeons (ASBrS) Resource Guide Update Recommends Cryoablation for Low-Risk Breast Cancer	PR
23/02	IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026	PR
20/02	IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation	AQ
12/02	IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense	AQ
09/02	IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved	PR
28/01	IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer	PR
12/01	IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales	PR